These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 33865530)

  • 1. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.
    Ramakumar V; Benz AP; Karthikeyan G
    Indian Heart J; 2021; 73(2):244-248. PubMed ID: 33865530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
    Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
    da Silva RMFL
    Cardiovasc Hematol Agents Med Chem; 2022; 20(3):172-174. PubMed ID: 35319395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
    Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
    J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
    Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
    Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
    Anderson SL; Marrs JC
    Curr Cardiol Rep; 2019 Aug; 21(10):118. PubMed ID: 31473836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry.
    Márquez MF; Baños-González MA; Guevara-Valdivia ME; Vázquez-Acosta J; de Los Ríos Ibarra MO; Aguilar-Linares JA; Jiménez-Cruz M; Matadamas-Hernández N; Camacho-Casillas R; Magaña-Magaña R; Rojel-Martínez U; Alcocer-Gamba MA; Lara-Vaca S; Rodríguez-Reyes H; Islava-Gálvez MA; Betancourt-Hernández LE; Reyes-Reyes N; Beltrán-Gámez ME; Cantú-Brito C; Baños-Velasco AZ; Del Rivero Morfin PJ; González-Hermosillo JA
    Glob Heart; 2020 Apr; 15(1):32. PubMed ID: 32489805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for rheumatic mitral stenosis, INVICTUS in perspective.
    Verma R; Latter DA
    Curr Opin Cardiol; 2023 Mar; 38(2):55-60. PubMed ID: 36718615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.
    Polo García J; Vargas Ortega D; Formiga F; Unzueta I; Fernández de Cabo S; Chaves J
    Semergen; 2019 Sep; 45(6):396-405. PubMed ID: 30573367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.
    Marzec LN; Wang J; Shah ND; Chan PS; Ting HH; Gosch KL; Hsu JC; Maddox TM
    J Am Coll Cardiol; 2017 May; 69(20):2475-2484. PubMed ID: 28521884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update.
    Ha AC; Verma A; Verma S
    Curr Opin Cardiol; 2017 Mar; 32(2):174-180. PubMed ID: 27861189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.